ストックスクリーナーアプリを入手
8.90
6.59%
0.55
前日終値:
$8.35
開ける：
$8.48
24時間の取引高:
5.88M
Relative Volume:
15.70
時価総額：
$571.38M
収益：
-
当期純損益:
$-106.19M
株価収益率:
-4.9112
EPS:
-1.8122
ネットキャッシュフロー:
$-85.19M
1週間 パフォーマンス:
+27.87%
1か月 パフォーマンス:
+36.09%
6か月 パフォーマンス:
+63.60%
1年 パフォーマンス:
+50.34%
1日の値動き範囲:
$8.43
$9.535
1週間の範囲:
$6.6495
$9.535
52週間の値動き範囲:
$4.345
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
8.90 | 571.38M | 0 | -106.19M | -85.19M | -1.8122 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-26 | 再開されました | Evercore ISI | Outperform |
| 2025-05-28 | 再開されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-07-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Aura Biosciences Inc (AURA) 最新ニュース
Aura Biosciences Announces $39.6 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement with Leerink Partners, TD Securities, and Evercore Group - Minichart
Aura Biosciences Completes Major Underwritten Equity Financing - TipRanks
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Aura Biosciences closes $299.4 million public offering By Investing.com - Investing.com Canada
Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buyback - Stock Titan
Aura raises $299M as underwriters take full extra-share option - Stock Titan
Aura Biosciences (NASDAQ: AURA) offers 39.6M shares, repurchase $39M - Stock Titan
Norwegian Cruise Line, Aura Biosciences and other big stocks moving lower in Monday's pre-market session - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder - TipRanks
Aura Biosciences (NASDAQ: AURA) plans 6.9M-share Matrix buyback - Stock Titan
Aura Biosciences launches public offering of common stock By Investing.com - Investing.com India
Aura Biosciences Appoints New CEO as Phase 3 CoMpass Trial for Belzupacap Sarotalocan Nears Enrollment Completion - Minichart
Aura Biosciences names Natalie Holles as new CEO By Investing.com - Investing.com South Africa
Aura Biosciences names Natalie Holles as new CEO - Investing.com UK
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big - Benzinga
Aura Biosciences prices $260.3M stock offering at $6/share - Investing.com
Aura Biosciences prices $260M stock, warrant offering - MSN
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants - The Manila Times
Aura Biosciences announces pricing of $260 million public offering of common stock and pre-funded warrants - marketscreener.com
Aura Biosciences prices $260.3M stock offering at $6/share By Investing.com - Investing.com UK
Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Aura raises $260.3M, earmarks part to buy out Matrix stake - Stock Titan
Orion Corporation: Managers’ transactions – Kari Jussi Aho - Weekly Voice
Aura Biosciences Appoints Natalie Holles CEO as Phase 3 Trial Nears Enrollment Completion - citybiz
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Aura Biosciences (AURA) offers stock and pre-funded warrants; plans possible Matrix buyback - Stock Titan
Aura Biosciences Names Natalie Holles as CEO, Plans Public Offering - marketscreener.com
Aura Biosciences Advances CoMpass Phase 3 Trial Progress - TipRanks
Aura Biosciences launches public offering of common stock - Investing.com
New Aura Biosciences (NASDAQ: AURA) CEO as Phase 3 CoMpass trial nears enrollment - Stock Titan
Aura seeks fresh capital with stock sale and pre-funded warrants - Stock Titan
New Aura CEO arrives as eye cancer trial nears enrollment completion - Stock Titan
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Aura Biosciences, Inc. Announces Board and Executive Changes, Effective April 30, 2026 - marketscreener.com
Are medical stocks lagging Aura Biosciences (AURA) this year? - MSN
AURA SEC FilingsAura Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(AURA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
Aura Biosciences, Inc. (AURA) just flashed golden cross signal: Do you buy? - MSN
Is Aura Biosciences (AURA) stock outpacing its medical peers this year? - MSN
Aura Bio (AURA) Stock: Stability Check (Smart Money Flows) 2026-04-22Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year? - Yahoo Finance
Aura Biosciences (NASDAQ: AURA) outlines 2026 vote on directors and auditor - Stock Titan
Aura Bio (AURA) Stock Forecast (Smart Money Exits) 2026-04-20Trending Momentum Stocks - Xã Thanh Hà
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect? - Yahoo Finance
(AURA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AURA Aura Biosciences Inc. reports narrower Q4 2025 loss than estimates, shares climb 3.26 percent on positive investor sentiment.Momentum Score - Newser
Aura Biosciences Inc (AURA) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):